Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14656566.2021.1898589 http://scihub22266oqcxt.onion/10.1080/14656566.2021.1898589 33724123!7989952!33724123     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Opin+Pharmacother 2021 ; 22 (10): 1257-1266 Nephropedia Template TP {{tp|p=33724123|t=2021. Does hydroxychloroquine still have any role in the COVID-19 pandemic?|pdf=|usr=}}{{33724123}} gab.com Text Does hydroxychloroquine still have any role in the COVID-19 pandemic JO: Expert Opin Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=33724123 #FOAvip Introduction: The 4-aminoquinolines, chloroquine, and hydroxychloroquine have been used for over 70 years for malaria and rheumatological conditions, respectively. Their broad-spectrum antiviral activity, excellent safety profile, tolerability, low cost, and ready availability made them prime repurposing therapeutic candidates at the beginning of the COVID-19 pandemic.Areas covered: Here, the authors discuss the history of hydroxychloroquine and chloroquine, the in vitro data which led to their widespread repurposing and adoption in COVID-19 and their complex pharmacokinetics. The evidence for the use of these drugs is assessed through in vivo animal experiments and the wealth of conflicting data and interpretations published during COVID-19, including the more informative results from randomized controlled trials (RCTs). The safety aspects of these drugs, in particular cardiotoxicity, are then reviewed.Expert opinion: The evidence from clinical trials in COVID-19 supports the well-established safety record of the 4-aminoquinolines at currently recommended dosage. In hospitalized patients with severe COVID-19 RCTs show clearly that the 4-aminoquinolines are not beneficial. The only treatments with proven benefit at this stage of infection are immunomodulators (dexamethasone, IL-6 receptor antagonists). No antiviral drugs have proven life-saving in late-stage COVID-19. Twit Text FOAVip Does hydroxychloroquine still have any role in the COVID-19 pandemic ????Expert Opin Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=33724123 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33724123 #FOAvip English Wikipedia <ref>{{Cite pmid|33724123}}</ref> Does hydroxychloroquine still have any role in the COVID-19 pandemic? #MMPMID33724123 Schilling WH; White NJ Expert Opin Pharmacother 2021[Jul]; 22 (10): 1257-1266 PMID33724123show ga Introduction: The 4-aminoquinolines, chloroquine, and hydroxychloroquine have been used for over 70 years for malaria and rheumatological conditions, respectively. Their broad-spectrum antiviral activity, excellent safety profile, tolerability, low cost, and ready availability made them prime repurposing therapeutic candidates at the beginning of the COVID-19 pandemic.Areas covered: Here, the authors discuss the history of hydroxychloroquine and chloroquine, the in vitro data which led to their widespread repurposing and adoption in COVID-19 and their complex pharmacokinetics. The evidence for the use of these drugs is assessed through in vivo animal experiments and the wealth of conflicting data and interpretations published during COVID-19, including the more informative results from randomized controlled trials (RCTs). The safety aspects of these drugs, in particular cardiotoxicity, are then reviewed.Expert opinion: The evidence from clinical trials in COVID-19 supports the well-established safety record of the 4-aminoquinolines at currently recommended dosage. In hospitalized patients with severe COVID-19 RCTs show clearly that the 4-aminoquinolines are not beneficial. The only treatments with proven benefit at this stage of infection are immunomodulators (dexamethasone, IL-6 receptor antagonists). No antiviral drugs have proven life-saving in late-stage COVID-19. |*COVID-19 Drug Treatment[MESH] |*Hydroxychloroquine/therapeutic use[MESH] |Animals[MESH] |Antiviral Agents/therapeutic use[MESH] |Humans[MESH] |Pandemics[MESH]Does hydroxychloroquine still have any role in the COVID-19 pandemic?(epmc).pdf DeepDyve Pubget Overpricing